NasdaqCM:TGTXBiotechs
The Bull Case For TG Therapeutics (TGTX) Could Change Following New Azer-cel Milestone In Progressive MS
In early March 2026, Precision BioSciences announced it had reached a clinical milestone under its licensing agreement with TG Therapeutics for azercabtagene zapreleucel in progressive multiple sclerosis, triggering a US$7.5 million milestone payment, including US$5.25 million in cash and a US$2.25 million equity purchase.
This progress adds azer-cel as a differentiated autoimmune program alongside TG Therapeutics’ BRIUMVI franchise, potentially broadening its MS-focused treatment portfolio...